Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial.

J Clin Psychopharmacol · 2025 · PMC12105956 · PMID 40199329

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although a statistically significant improvement in HAMD-17 was observed at week 4, the continued improvement did not reach statistical significance at week 8 (primary endpoint).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.